-- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading
agency and financial media network dedicated to the North American
cannabis industry, announces publication of an article
featuring Aleafia Health Inc. (TSX-V: ALEF) (OTC: ALEAF)
(FRA: ARAH). The company is well-equipped to study the effects of
cannabis with its wholly-owned network of more than 20 Canabo
Medical Clinics with over 50,000 patients. These clinics provide
the company with the largest medical cannabis dataset in the world,
enabling researchers to validate cannabis sciences, product teams
to develop innovative new products, and management to build a
strong IP portfolio. Aleafia Health’s research division generated
$612,000 in revenue in Q3 2018, and the Company is building on that
success.
Medical cannabis research is only starting to scratch the
surface of how cannabinoids could play a role in areas
traditionally dominated by prescription pharmaceuticals. Given the
massive size of the pharmaceutical industry, these insights could
translate to significant value for first-movers in large
indications. The problem is that there’s limited data given the
newness and fragmentation of the global cannabis industry.
Advancing Cannabis Research
Aleafia Health’s two largest clinical studies were its
benzodiazepine study published earlier this year and its sleep
study that began in September of last year. These studies are just
starting to scratch the surface of what’s possible with the
company’s massive clinical presence and expert teams of physicians
and researchers. Many cannabis companies are eager to gather the
data needed to support their medical products.
The company recently published a retrospective study
that looked at benzodiazepine use among medical cannabis patients.
Researchers found that 45.2 percent of patients regularly consuming
benzodiazepines had stopped taking the medication within about six
months of becoming medical cannabis patients at its Canabo Medical
Clinics. The results were published in the peer-reviewed journal,
Cannabis and Cannabinoid Research, in January.
In September, Aleafia Health initiated a joint medical cannabis
study to improve the management and treatment of insomnia and
daytime sleepiness with the Cronos Group Inc.. The
company formally launched Aleafia Labs during the
following month as a way to formalize its research activities using
its existing patient database and intellectual property, with a
focus on addicting prescription opioids and sleeping aids.
Leveraging Big Data Insights
The launch of Aleafia Labs enabled Aleafia Health to
institutionalize its research offerings. By tracking all patient
interactions, the company generates significant datasets that are
hosted on Amazon AWS and visualized with Google Data Studio. During
the third quarter, the company generated more than $600,000 in
revenue from these research offerings, primarily from medical
cannabis companies subscribing to its proprietary medical cannabis
patient dataset.
Earlier this month, the company hired a Product Data
Science Fellow, Dr. Graham Merry, MD, to lead its evidence-based
product research efforts by leveraging its proprietary ten million
point patient dataset following its recent acquisition of a
licensed producer. Current research efforts include partnerships
with Cronos Group, Guided 420 Genetics, and AKESOgen, which could
result in meaningful insights for patients and physicians over the
coming months.
“I have been tremendously impressed with the whole team at
Aleafia while working in this field,” said Dr. Merry. “This
initiative will allow the opportunity to obtain clinical evidence
to validate and gain wider acceptance in the medical community
realizing the benefits of cannabinoid treatment in serious and
debilitating disease. Together we will make a huge difference in
addressing the unmet needs of patients in this emerging field of
medicine.”
Looking Ahead
Aleafia Health Inc. (TSX-V: ALEF) (OTC: ALEAF) (FRA: ARAH)
is well positioned to advance cannabinoid science with its massive
medical cannabis patient datasets and leading team of researchers.
In addition to generating revenue from research activities, the
company will leverage these insights to develop and launch its own
evidence-based cannabis products targeting a wide range of
indications, including pain management and sleep.
For more information, visit the company’s website
at https://www.aleafiainc.com/invest/
Click Here to Download Aleafia Health Inc.’s Investor
Presentation
Please follow the link to read the full article:
https://www.cannabisfn.com/aleafia-health-helps-patients-investors-with-revenue-generating-research/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media
network dedicated to the global cannabis industry, helps companies
operating in the space attract investors, capital, and publicity.
Since 2013, private and public cannabis companies in the US and
Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or
entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of
cannabis from the palm of your
hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the
Apple App Store logo to receive a download link text on your
iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment
advisor or broker-dealer. You should always consult with your own
independent legal, tax, and/or investment professionals before
making any investment decisions. The information provided
on http://www.cannabisfn.com (the ‘Site’) is either
original financial news or paid advertisements drafted by our
in-house team or provided by an affiliate. CannabisFN.com, a
financial news media and marketing firm enters into media buys or
service agreements with the companies that are the subject of the
articles posted on the Site or other editorials for advertising
such companies. We are not an independent news media
provider. We make no warranty or representation about the
information including its completeness, accuracy, truthfulness or
reliability and we disclaim, expressly and implicitly, all
warranties of any kind, including whether the Information is
complete, accurate, truthful, or reliable. As such, your use of the
information is at your own risk. Nor do we undertake any obligation
to update the items posted. CannabisFN.com received compensation
for producing and presenting high quality and sophisticated content
on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC,
which owns CannabisFN.com and CFN Media, has been hired to create
awareness. Please follow the link below to view our full disclosure
outlining our
compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane 206-369-7050Flane@cannabisfn.com
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From May 2024 to Jun 2024
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jun 2023 to Jun 2024